137 related articles for article (PubMed ID: 37691236)
1. Target Occupancy and Functional Inhibition of JAK3 and TEC Family Kinases by Ritlecitinib in Healthy Adults: An Open-Label, Phase 1 Study.
Martin DA; Telliez JB; Pleasic-Williams S; Zhang Y; Tierney B; Blatnik M; Gale JD; Banfield C; Zhou Y; Lejeune A; Zwillich SH; Stevens E; Tiwari N; Kieras E; Karanam A
J Clin Pharmacol; 2024 Jan; 64(1):67-79. PubMed ID: 37691236
[TBL] [Abstract][Full Text] [Related]
2. Reconstitution of Btk signaling by the atypical tec family tyrosine kinases Bmx and Txk.
Tomlinson MG; Kurosaki T; Berson AE; Fujii GH; Johnston JA; Bolen JB
J Biol Chem; 1999 May; 274(19):13577-85. PubMed ID: 10224128
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK.
Forster M; Liang XJ; Schröder M; Gerstenecker S; Chaikuad A; Knapp S; Laufer S; Gehringer M
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291717
[TBL] [Abstract][Full Text] [Related]
4. Improvements in immune/melanocyte biomarkers with JAK3/TEC family kinase inhibitor ritlecitinib in vitiligo.
Guttman-Yassky E; Del Duca E; Da Rosa JC; Bar J; Ezzedine K; Ye Z; He W; Hyde C; Hassan-Zahraee M; Yamaguchi Y; Peeva E
J Allergy Clin Immunol; 2024 Jan; 153(1):161-172.e8. PubMed ID: 37777018
[TBL] [Abstract][Full Text] [Related]
5. PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor.
Xu H; Jesson MI; Seneviratne UI; Lin TH; Sharif MN; Xue L; Nguyen C; Everley RA; Trujillo JI; Johnson DS; Point GR; Thorarensen A; Kilty I; Telliez JB
ACS Chem Biol; 2019 Jun; 14(6):1235-1242. PubMed ID: 31082193
[TBL] [Abstract][Full Text] [Related]
6. Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/Tec kinases in platelets induced by collagen binding or CD32 cross-linking.
Oda A; Ikeda Y; Ochs HD; Druker BJ; Ozaki K; Handa M; Ariga T; Sakiyama Y; Witte ON; Wahl MI
Blood; 2000 Mar; 95(5):1663-70. PubMed ID: 10688822
[TBL] [Abstract][Full Text] [Related]
7. Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib.
Hopper M; Gururaja T; Kinoshita T; Dean JP; Hill RJ; Mongan A
J Pharmacol Exp Ther; 2020 Mar; 372(3):331-338. PubMed ID: 31871305
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel dual Bruton's tyrosine kinase (BTK) and Janus kinase 3 (JAK3) inhibitors as a promising strategy for rheumatoid arthritis.
Liang T; Cen L; Wang J; Cheng M; Guo W; Wang W; Yu C; Zhang H; Wang Y; Hao Z; Jin J; Wu Y; Jiang T; Zhu Q; Xu Y
Bioorg Med Chem; 2023 Dec; 96():117354. PubMed ID: 37944414
[TBL] [Abstract][Full Text] [Related]
9. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
[TBL] [Abstract][Full Text] [Related]
10. Expression and function of Tec, Itk, and Btk in lymphocytes: evidence for a unique role for Tec.
Tomlinson MG; Kane LP; Su J; Kadlecek TA; Mollenauer MN; Weiss A
Mol Cell Biol; 2004 Mar; 24(6):2455-66. PubMed ID: 14993283
[TBL] [Abstract][Full Text] [Related]
11. Dual functions of Bruton's tyrosine kinase and Tec kinase during Fcgamma receptor-induced signaling and phagocytosis.
Jongstra-Bilen J; Puig Cano A; Hasija M; Xiao H; Smith CI; Cybulsky MI
J Immunol; 2008 Jul; 181(1):288-98. PubMed ID: 18566394
[TBL] [Abstract][Full Text] [Related]
12. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
Ringheim GE; Wampole M; Oberoi K
Front Immunol; 2021; 12():662223. PubMed ID: 34803999
[TBL] [Abstract][Full Text] [Related]
13. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
14. Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers.
Litzenburger T; Steffgen J; Benediktus E; Müller F; Schultz A; Klein E; Ramanujam M; Harcken C; Gupta A; Wu J; Wiebe S; Li X; Flack M; Padula SJ; Visvanathan S; Hünnemeyer A; Hui J
Br J Clin Pharmacol; 2021 Apr; 87(4):1824-1838. PubMed ID: 32986868
[TBL] [Abstract][Full Text] [Related]
15. The accessory factor Nef links HIV-1 to Tec/Btk kinases in an Src homology 3 domain-dependent manner.
Tarafdar S; Poe JA; Smithgall TE
J Biol Chem; 2014 May; 289(22):15718-28. PubMed ID: 24722985
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial.
Ezzedine K; Peeva E; Yamaguchi Y; Cox LA; Banerjee A; Han G; Hamzavi I; Ganesan AK; Picardo M; Thaçi D; Harris JE; Bae JM; Tsukamoto K; Sinclair R; Pandya AG; Sloan A; Yu D; Gandhi K; Vincent MS; King B
J Am Acad Dermatol; 2023 Feb; 88(2):395-403. PubMed ID: 36370907
[TBL] [Abstract][Full Text] [Related]
17. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
King B; Soung J; Tziotzios C; Rudnicka L; Joly P; Gooderham M; Sinclair R; Mesinkovska NA; Paul C; Gong Y; Anway SD; Tran H; Wolk R; Zwillich SH; Lejeune A
Am J Clin Dermatol; 2024 Mar; 25(2):299-314. PubMed ID: 38263353
[TBL] [Abstract][Full Text] [Related]
18. Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants.
Catlett IM; Nowak M; Kundu S; Zheng N; Liu A; He B; Girgis IG; Grasela DM
Br J Clin Pharmacol; 2020 Sep; 86(9):1849-1859. PubMed ID: 32198939
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers.
Smith PF; Krishnarajah J; Nunn PA; Hill RJ; Karr D; Tam D; Masjedizadeh M; Funk JO; Gourlay SG
Br J Clin Pharmacol; 2017 Nov; 83(11):2367-2376. PubMed ID: 28636208
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Nef dimers short-circuit immune receptor signaling by activating Tec-family kinases at the host cell membrane.
Li WF; Aryal M; Shu ST; Smithgall TE
J Biol Chem; 2020 Apr; 295(15):5163-5174. PubMed ID: 32144207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
